dr catenacci university of chicago

Catenacci, Mitesh J. Borad, John Bridgewater, William P. Harris, Adrian Murphy, Do Youn Oh, Jonathan R. Whisenant, Maeve A. Lowery, Lipika Goyal, Rachna T. Shroff, Anthony B. El-Khoueiry, Bin Fan, Bin Wu, Christina X. Chamberlain, Liewen Jiang, Camelia Gliser, Shuchi Sumant Pandya, Juan W. Valle, Andrew X. Zhu, The Chicago Consensus on peritoneal surface malignancies: Management of desmoplastic small round cell tumor, breast, and gastrointestinal stromal tumors, Francisco J. Izquierdo, Alejandro Plana, Darryl Schuitevoerder, Andrea Hayes-Jordan, Jeremiah L. Deneve, Mazin AlKasspooles, Wilbur B. Bowne, Charles Komen Brown, John M. Kane, Kaitlyn J. Kelly, Timothy J. Kennedy, Ugwuji N. Maduekwe, Grace Z. Mak, Marcovalerio Melis, Richard E. Royal, Daniel E. Abbott, Sherif Abdel-Misih, Farin Amersi, Amanda K. Arrington, Brian D. Badgwell, Robert M. Barone, Joel M. Baumgartner, Richard N. Berri, Lana Bijelic, Dan G. Blazer, Daniel V.T. Catenacci, Alexander T. Pearson, Sandeep Parsad, Keith Danahey, Xander M R van Wijk, Kiang-Teck J. Yeo, Mark J. Ratain, Peter H. O'Donnell, Spatial and Temporal Heterogeneity of PD-L1 Expression and Tumor Mutational Burden in Gastroesophageal Adenocarcinoma at Baseline Diagnosis and after Chemotherapy, Katherine I. Zhou, Bryan Peterson, Anthony Serritella, Joseph Thomas, Natalie Reizine, Stephanie Moya, Carol Tan, Yan Wang, Daniel V.T. Her2 expression in Gastroesophageal Cancer (GEC) FFPE Tissue using Mass Spectrometry (MS) and correlation with HER2 gene amplification. Prospective Comprehensive Genomic Profiling of Advanced Gastric Carcinoma Cases Reveals Frequent Clinically Relevant Genomic Alterations and New Routes for Targeted Therapies, Siraj M. Ali, Eric M. Sanford, Samuel J. Klempner, Douglas A. Rubinson, Kai Wang, Norma Alonzo Palma, Juliann Chmielecki, Roman Yelensky, Gary A. Palmer, Deborah Morosini, Doron Lipson, Daniel V.T. Catenacci, Gustavo M. Cervantes, Soheil Yala, Erik A. Nelson, Essam El-Hashani, Rajani Kanteti, Mohamed El Dinali, Rifat Hasina, Johannes Brgelmann, Tanguy Y. Seiwert, Michele Sanicola, Les Henderson, Tatyana A. Grushko, Olufunmilayo I. Olopade, Theodore Karrison, Yung-Jue Bang, Woo Ho Kim, Maria Tretiakova, Everett E. Vokes, David A. Frank, Hedy L. Kindler, Heather Huet, Ravi Salgia, Daniel V.T. Development of a clinical cMet SRM assay and assessment of assay precision in archival formalin fixed paraffin embedded (FFPE) sections. Throughout many of the discussions on BioTech IQ it is clear that a combination of therapies is likely the answer to treating cancers and other diseases. Dr. Samuel J. Klempner is an oncologist specializing in gastrointestinal cancers at Massachusetts General Hospital.. Dr. Eirini Pectasides is a medical oncologist at the Dana-Farber Cancer Institute specializing in gastrointestinal cancers.. Dr. Daniel V. T. Catenacci is an adult gastrointestinal medical oncologist and director of the Gastrointestinal Oncology Program at the University of Chicago. A University of Chicago associate professor who worked as a clinical trial investigator for Five Prime . KRAS gene amplification defines a distinct molecular subgroup of gastroesopahgeal adenocarcinoma that may benefit from combined anti-MEK/AKT therapy. Margetuximab (M) combined with anti-PD-1 (MGA012) or anti-PD-1/LAG-3 (MGD013) +/- chemotherapy (CTX) in first-line therapy of advanced/metastatic HER2+ gastroesophageal junction (GEJ) or gastric cancer (GC). Catenacci. Back in January 2021, Dr. Daniel V.T. Following this, Dr Catenacci held positions at . J E Berchuck, F Facchinetti, D F DiToro, I Baiev, U Majeed, S Reyes, C Chen, K Zhang, R Sharman, P L S Uson Junior, J Maurer, R T Shroff, C C Pritchard, M-J Wu, D V T Catenacci, M Javle, L Friboulet, A Hollebecque, N Bardeesy, A X Zhu, J K Lennerz, B Tan, M Borad, A R Parikh, L A Kiedrowski, R K Kelley, K Mody, D Juric, L Goyal. Open for more information, Community Physician Tumor mutational burden is predictive of response to immune checkpoint inhibitors in MSI-high metastatic colorectal cancer. Catenacci, Salah-Eddin Al-Batran, James Posey. Utility of Perioperative Measurement of Cell-Free DNA and Circulating Tumor DNA in Informing the Prognosis of GI Cancers: A Systematic Review. Home; . Novel Molecularly Targeted Therapies in Esophageal Cancer: Relevance of MET&RON. JC Bendell, H Hochster, LL Hart, I Firdaus, JR Mace, JJ McFarlane, M Kozloff, D Catenacci, J Hsu, S Hack, D Shames, S Phan, AL Cohn. Manish R. Sharma, Smita S. Joshi, Theodore Karrison, Kenisha Allen, Grace K. Suh, Robert de Wilton Marsh, Mark Kozloff, Blase N. Polite, Daniel V.T. Dr. Catenacci frequently treats Pancreatic Neoplasms and Gastrointestinal Neoplasms. Catenacci bought 8,743 shares of Five Prime Therapeutics Inc., knowing that the company was about to release positive results from a phase II study of bemarituzumab, a monoclonal [] (Invited Panelist). They use diagnostic tools like biopsies, endoscopies, X-ray and other imaging, nuclear medicine, and blood tests. The probe was first disclosed publicly in a lawsuit filed against Catenacci last week by the U.S. Securities and Exchange Commission. Daniel V.T. Catenaccis attorneys said in a statement Monday that Catenacci has been cooperating with the government since the beginning of the investigation., This is a complex area of the law, the statement read. Catenacci, Mitesh J. Borad, John Bridgewater, William P. Harris, Adrian Murphy, Do Youn Oh, Jonathan R. Whisenant, Maeve A. Lowery, Lipika Goyal, Rachna T. Shroff, Anthony B. El-Khoueiry, Christina X. Chamberlain, Elia Aguado-Fraile, Sung Choe, Bin Wu, Hua Liu, Camelia Gliser, Shuchi Sumant Pandya, Juan W. Valle, Ghassan K. Abou-Alfa. He subsequently went on to earn an MSc in Health Studies from the University of Chicago, Chicago, IL. High Performing in Colon Cancer Surgery, Lung Cancer Surgery, Ovarian Cancer Surgery and Prostate Cancer Surgery, Fellowship, Hematology and Medical Oncology, 2006-2010, UCLA David Geffen School of Medicine/UCLA Medical Center, Wayne State University School of Medicine, Best Abstract Translational Research Faculty Category, 2014, Best Abstract and Oral Presentation, 2013, Career Development LOI Awarded A Randomized Discontinuation Trial of OSI-906 in metastatic Colorectal Cancer After Two or More Lines of Prior Therapy, 2010, Distinguished Teacher Award for UCLA Interns and Medical Students, 2004, Inductee of Alpha Omega Alpha Honor Medical Society, 2001, William F. von Liebig Summer Research Fellowship, 2000, Nominated for the Governor Generals Silver Medal and Alumni Gold Medal for highest academic standing in Faculty of Science, 1999, Recipient of Sony of Canada Science Scholarship for highest academic standing, 1998, Deans Honors List, Undergraduate Year I to Year IV, 1995, Author Correction: Targeting Wild-Type KRAS-Amplified Gastroesophageal Cancer Through Combined MEK and SHP2 Inhibition, Daniel Catenacci, Adam J Bass, Shaunt Fereshetian, Rameen Beroukhim. Catenacci, Daniel D. Von Hoff, Carlos Becerra, Nancy Whiting, Jing Yang, Brian M. Wolpin, A Phase I Study of FOLFIRINOX Plus IPI-926, a Hedgehog Pathway Inhibitor, for Advanced Pancreatic Adenocarcinoma, Andrew H. Ko, Noelle K. LoConte, Margaret A. Tempero, Evan J. Walker, R. Kate Kelley, Stephanie Lewis, Wei-Chou Chang, Emily Kantoff, Michael W. Vannier, Daniel V.T. MET tyrosine kinase receptor expression and amplification as prognostic biomarkers of survival in gastroesophageal adenocarcinoma. ACR Appropriateness Criteria Staging and Follow-Up of Esophageal Cancer. Expansion platform type II: testing a treatment strategy. Cohen DJ, Christos PJ, Catenacci DVT, Kindler HL, Bekaii-Saab TB, Tahiri S, Janjigian YY, Gibson MK, Chan E, Rajdev L, Urba S, Wade JL, Kozuch P, Love E, Vandris K, Takebe N, Hochster HS, Sparano JA, A randomized pilot phase I study of modified Carcinoembryonic antigen (CEA) peptide (CAP1-6D)/Montanide/GM-CSF-vaccine (CEA-vac) in patients (pts) with pancreatic adenocarcinoma (PC), Geynisman DM, Zha Y, Kunnavakkam R, Aklilu D, Catenacci DVT, Polite BN, Rosenbaum A, Namakydoust A, Karrison T, Gajewski TF, Kindler HL. Catenacci, Fadi Braiteh, Rachel L. Erlich, Philip J. Stephens, Jeffrey S. Ross, Sai-Hong Ignatius Ou, Vincent A. Miller. Dr. Catenacci is building on this published work, using a nude mouse model with a shRNA RON gastric . (773) 702-6149. Catenacci is an associate professor of medicine, according to his LinkedIn profile and biography on the University of Chicago's website. Dr. Catenacci is of the University of Chicago Medical Center and Biological Sciences. This was according to Daniel V.T. This provider currently accepts 29 insurance plans. dr catenacci university of chicago. View hours, services and more. Exploratory PD-L1 expression on extracellular vesicles is interesting. Catenacci, Carlos H. F. Chan, David B. Chapel, Clifford S. Cho, M. Haroon A. Choudry, Callisia N. Clarke, James C. Cusack, Abraham H. Dachman, Jeremiah L. Deneve, Sean P. Dineen, Oliver S. Eng, Leopoldo J. Fernandez, James Fleshman, T. Clark Gamblin, Alexandra Gangi, Georgios V. Georgakis, Erin W. Gilbert, Martin D. Goodman, Travis E. Grotz, Vadim Gushchin, Nader Hanna, Carla Harmath, Andrea Hayes-Jordan, Aliya N. Husain, Kamran Idrees, Chukwuemeka Ihemelandu, Fabian M. Johnston, David Jiang, John M. Kane, Giorgos C. Karakousis, Kaitlyn J. Kelly, Timothy J. Kennedy, Xavier M. Keutgen, Hedy L. Kindler, Michael D. Kluger, Ricardo R. Lastra, Byrne Lee, Lloyd A. Mack, Ugwuji N. Maduekwe, Grace Z. Mak, Joshua M. V. Mammen, Melvy Sarah Mathew, Marcovalerio Melis, Nelya Melnitchouk, Ryan P. Merkow, Harveshp Mogal, Mecker G. Mller, John Moroney, Aytekin Oto, Colette R. Pameijer, Sam G. Pappas, Patricio M. Polanco, Blase N. Polite, Sanjay S. Reddy, Richard E. Royal, George I. Salti, Armando Sardi, Maheswari Senthil, Namrata Setia, Scott K. Sherman, Lucas Sideris, Joseph Skitzki, Sandy Tun, Jula Veerapong, Konstantinos I. Votanopoulos, Michael G. White, Joshua H. Winer, Shu-Yuan Xiao, Rhonda K. Yantiss, Nita Ahuja, Andrew M. Lowy, H. Richard Alexander, Jesus Esquivel, Jason M. Foster, Daniel M. Labow, Laura A. Lambert, Edward A. Levine, Charles A. Staley, Paul H. Sugarbaker, David L. Bartlett, Kiran K. Turaga, Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study, Ghassan K. Abou-Alfa, Teresa Macarulla, Milind Javle, Robin Kate Kelley, Sam J. Lubner, Jorge Adeva, James M. Cleary, Daniel V.T. Search below to find a doctor with that skillset. Andrew X. Zhu, Teresa Macarulla, Milind Javle, R. Kate Kelley, Sam J. Lubner, Jorge Adeva, James M. Cleary, Daniel V.T. FIGHT: A phase 3 randomized, double-blind, placebo controlled study evaluating (bemarituzumab) FPA144 and modified FOLFOX6 (mFOLFOX6) in patients with previously untreated advanced gastric and gastroesophageal cancer with a dose finding phase 1 lead-in. Daniel V.T. Catenacci, Harry H. Yoon, Erluo Chen, David Adelberg, Chie-Schin Shih, Sukrut Shah, Pooja Bhagia, Zev A. Wainberg. Catenacci, Amy C. Peterson, Mark J. Ratain, Blase N. Polite, Janice M. Mehnert, Rebecca A. Moss, New Routes to Targeted Therapy of Intrahepatic Cholangiocarcinomas Revealed by Next-Generation Sequencing, Jeffrey S. Ross, Kai Wang, Rami N. Al-Rohil, Janne V. Rand, David M. Jones, Hwa J. Lee, Christine E. Sheehan, Geoff Otto, Gary A. Palmer, Roman Yelensky, Doron Lipson, Deborah Morosini, Matthew J. Hawryluk, Daniel V.T. In November 2020, as the company was readying to publicly announce positive results from the trial, Catenacci secretly purchased more than 8,000 shares in Company A securities, according to the charges. History. Dr Catenacci is board certified in medical oncology. Next-generation companion diagnostics: promises, challenges, and solutions. Catenacci, Theodore Karrison, Jaclyn D Peterson, Mark M. Zalupski, Amikar Sehdev, James L. Wade, Ahad Ali Sadiq, Vincent J. Picozzi, Andrea Amico, Robert de Wilton Marsh, Mark Kozloff, Blase N. Polite, Hedy L. Kindler, Manish R. Sharma, Circulating Tumor DNA Sequencing Analysis of Gastroesophageal Adenocarcinoma, Steven Brad Maron, Leah Chase, Samantha Lomnicki, Sara Kochanny, Kelly Moore, Smita S. Joshi, Stacie Landron, Julie K. Johnson, Lesli A. Kiedrowski, Rebecca J. Nagy, R.B. Ronan J. Kelly, Jeeyun Lee, Yung-Jue Bang, Khaldoun Almhanna, Mariela Blum-Murphy, Daniel V.T. Gain a better understanding of fertility as we explore what happens during ovulation and how to get pregnant. Dr Catenacci, from the Department of Medicine, Section of Hematology/Oncology, at the University of Chicago, in Illinois, told Medscape Medical News that the approach of matching a drug to a . Dr. John Hart is the Vice Chair of Anatomic Pathology at the University of Chicago Medical Center. Biliary cancer: Utility of next-generation sequencing for clinical management. gastric cancer. Conditions & Services; Patients & Visitors; Healthcare Professionals; Research; Comer Children's Hospital; Community Engagement; International Programs; About Us; A Contreras, R Purcell, DVT Catenacci, TK Hale, M Tretiakova, R Salgia, M Sullivan, J Hart. Catenacci. jiromuanya@uchicago.edu. The information charges Dr. Catenacci, 45, of Chicago, with one count of securities fraud. 5841 S Maryland Avenue, Chicago, IL 60637 map. Elena Elimova, Yelena Y. Janjigian, Mary F. Mulcahy, Daniel V.T. Moderated Roundtable Discussion: Defining the major knowledge gaps and priorities for future research of cholangiocarcinoma. DVT Catenacci, L Zhao, E Whitcomb, L Henderson, E O'Day, P Xu, SY Xiao, SM Lee, WL Liao, SP Thyparambil, J Uzzell, M Darfler, D Krizman, J Burrows, TA Hembrough, Relationship Between PD-L1 Expression and Clinical Outcomes in Patients (Pts) With Advanced Gastric Cancer Treated With the Anti-PD-1 Monoclonal Antibody Pembrolizumab. Catenacci. Daniel Catenacci was a lead physician and investigator for a Phase 2 trial of a stomach . Closed now. Stiff, Pankaj Kumar, Peng Xu, Les Henderson, Naoko Takebe, Ravi Salgia, Xi Wang, Walter M. Stadler, Frederic J. de Sauvage, Hedy L. Kindler, Acquisition of Portal Venous Circulating Tumor Cells From Patients With Pancreaticobiliary Cancers by Endoscopic Ultrasound, Daniel V.T. Dr. Daniel V. Catenacci is an oncologist in Chicago, Illinois and is affiliated with University of Chicago Medical Center.He received his medical degree from Wayne State University School of . Dr. Daniel Catenacci, MD is a Medical Oncology Specialist in Chicago, IL. Dan Catenacci (U Chicago) dcatenac@bsd.uchicago.edu. Tomasz Oliwa, Steven Brad Maron, Leah Chase, Samantha Lomnicki, Daniel V.T. Catenacci, Pembrolizumab alone or in combination with chemotherapy as first-line therapy for patients with advanced gastric or gastroesophageal junction adenocarcinoma: results from the phase II nonrandomized KEYNOTE-059 study, Yung Jue Bang, Yoon-Koo Kang, Daniel V.T. Catenacci, Brian Furner, Samuel L. Volchenboum, FGFR2Altered Gastroesophageal Adenocarcinomas Are an Uncommon Clinicopathologic Entity with a Distinct Genomic Landscape, Samuel J. Klempner, Russell Madison, Vivek Pujara, Jeffrey S. Ross, Vincent A. Miller, Siraj M. Ali, Alexa B. Schrock, Seung Tae Kim, Steven Brad Maron, Farshid Dayyani, Daniel V.T. Targeted Therapies A New Generation of Cancer Treatments.. Hembrough T, Henderson L, Rambo B, Liao WL, Thyparambil S, Bengali K, Uzzell J, Darfler M, Krizman D, Xu P, Xiao SY, Zhao L, Burrows J, Catenacci DVT. Dr. Daniel Catenacci, MD, is an Internal Medicine specialist practicing in Chicago, IL with 19 years of experience. Ari Rosenberg, MD, is an oncologist who specializes in using basic, translation and clinical research to improve the lives of his patients. Phase II Prospective, Open-Label Randomized Controlled Trial Comparing Standard of Care Chemotherapy With and Without Sequential Cytoreductive Interventions for Patients with Oligometastatic Foregut Adenocarcinoma and Undetectable Circulating Tumor Deoxyribose Nucleic Acid (ctDNA) Levels. Dr. Catenacci serves as an associate editor for the Journal of American Medical Association Network Open (JAMA Netw Open) and is on the editorial board of the Journal of Clinical Oncology . V Cohen DJ, Christos PJ, Sparano JA, Catenacci DVT, Kindler HL, Bekaii-Saab TB, Tahiri S, Yuriy Y, Givson MK, Chan E, Rajdev L, Urba S, Wade JL, Kozuch P, Love E, Vandris K, Takebe N, Hochster HS. Daniel Catenacci, MD, medical oncologist, assistant professor of medicine, University of Chicago . . Gastroesophageal Junction Adenocarcinoma: Is There an Optimal Management? Daniel M. Geynisman, Daniel V.T. Analysis of Circulating Tumor DNA to Predict Risk of Recurrence in Patients With Esophageal and Gastric Cancers. The authors thank L. Jeffrey Medeiros, MD, for critical review of this manuscript. Catenacci, Niall C. Tebbutt, Irina Davidenko, Andre M. Murad, Salah-Eddin Al-Batran, David H. Ilson, Sergei Tjulandin, Evengy Gotovkin, Boguslawa Karaszewska, Igor Bondarenko, Mohamedtaki Abdulaziz Tejani, Anghel Adrian Udrea, Mustapha Tehfe, Ferdinando De Vita, Cheryl Turkington, Rui Tang, Agnes Ang, Yilong Zhang, Tien Hoang, Roger Sidhu, David Cunningham. Evaluation of MET as a Prognostic Biomarker Determined by FISH, IHC, or Mass Spectrometry in Patients With Gastroesophageal Cancer. Catenacci is an associate professor of medicine and oncologist, according to his LinkedIn profile and biography on the University of Chicago's Web site. Call or Book Online. FOLFIRINOX as first-line therapy in patients with metastatic gastroesophageal cancers (GEC). (773) 702-2371. (Plenary Session ORAL Presentation & Best Abstract Award). Oncologists diagnose and treat cancers of all types. Dr. Catenacci, Hedy L. Kindler, Daniel V.T. Chih-Yi (Andy) Liao, MD Catenacci, Andrea Amico, Sarah M. Nielsen, Daniel M. Geynisman, Brittany Rambo, George B. Carey, Cassandra Gulden, Jim Fackenthal, Robert de Wilton Marsh, Hedy L. Kindler, Olufunmilayo I. Olopade. Catenacci, Dana C. Deighton, Karyn A. Goodman, Narinder K. Malhotra, Christopher G. Willett, Brendon M. Stiles, Prateek Sharma, Laura H. Tang, Bas P. L. Wijnhoven, Wayne L. Hofstetter, The Chicago Consensus on peritoneal surface malignancies: Management of peritoneal mesothelioma, Darryl Schuitevoerder, Francisco J. Izquierdo, Alejandro Plana, Garrett M. Nash, Leopoldo J. Fernandez, Michael D. Kluger, Lloyd A. Mack, Joshua M. V. Mammen, Colette R. Pameijer, Patricio M. Polanco, Lucas Sideris, Joseph Skitzki, Daniel E. Abbott, Sherif Abdel-Misih, Steven A. Ahrendt, Mazin AlKasspooles, Farin Amersi, Amanda K. Arrington, Brian D. Badgwell, Robert M. Barone, Joel M. Baumgartner, Richard N. Berri, Lana Bijelic, Dan G. Blazer, Wilbur B. Bowne, Charles Komen Brown, Daniel V.T. A randomized phase II study of vismodegib (V), a hedgehog (HH) pathway inhibitor, combined with FOLFOX in patients (pts) with advanced gastric and gastroesophageal junction (GEJ) carcinoma: A New York Cancer Consortium led study. U.S. District Judge Jorge L. Alonso ordered Dr. Daniel V.T. Catenacci, John Hart. Dr. Daniel Catenacci, MD is an oncologist in Chicago, Illinois. MD, in the Section of Gastroenterology at the University of Chicago. E An; WL Liao; S Thyparambil; J Rodriguez; R Salgia; II Wistuba; J Burrows; T Hembrough; DVT Catenacci, Absolute Quantitation of Met Using Mass Spectrometry for Clinical Application: Assay Precision, Stability, and Correlation with MET Gene Amplification in FFPE Tumor Tissue, Daniel V.T. In the morning of Nov. 10, 2020, Daniel V.T. Through this position, Catenacci allegedly received confidential information about the company and its clinical trial results. University of Chicago Comprehensive Cancer Center 2010 - Jan 2022 12 years. Zev A Wainberg, Peter C Enzinger, Yoon-Koo Kang, Shukui Qin, Kensei Yamaguchi, In-Ho Kim, Anwaar Saeed, Sang Cheul Oh, Jin Li, Haci Mehmet Turk, Alexandra Teixeira, Christophe Borg, Erika Hitre, Adrian A Udrea, Giovanni Gerardo Cardellino, Raquel Guardeo Sanchez, Helen Collins, Siddhartha Mitra, Yingsi Yang, Daniel V T Catenacci, Keun-Wook Lee. Author Correction: Targeting wild-type KRAS-amplified gastroesophageal cancer through combined MEK and SHP2 inhibition. Dr. Catenacci purchased more than 8,000 shares before the company . Catenacci, Alan P. Venook, Hedy L. Kindler. A randomized pilot phase I study of modified carcinoembryonic antigen (CEA) peptide (CAP1-6D)/montanide/GM-CSF-vaccine in patients with pancreatic adenocarcinoma, Daniel M. Geynisman, Yuanyuan Zha, Rangesh Kunnavakkam, Mebea Aklilu, Daniel V.T. Catenacci, Howard S. Hochster, Samuel J. Klempner. Catenacci, Wei-Li Liao, Sheeno Thyparambil, Les Henderson, Peng Xu, Lei Zhao, Brittany Rambo, John Hart, Shu-Yuan Xiao, Kathleen Bengali, Jamar Uzzell, Marlene Darfler, David B. Krizman, Fabiola Cecchi, Donald P. Bottaro, Theodore Karrison, Timothy D. Veenstra, Todd Hembrough, Jon Burrows, Phase I Dose-Escalation Study of Onartuzumab as a Single Agent and in Combination with Bevacizumab in Patients with Advanced Solid Malignancies, Ravi Salgia, Premal Patel, John Bothos, Wei Yu, Steve Eppler, Priti S. Hegde, Shuang Bai, Surinder Kaur, Ihsan Nijem, Daniel V.T. Validation of Microsatellite Instability Detection Using a Comprehensive Plasma-Based Genotyping Panel. Catenacci DVT, Xu P, Henderson L, Pijnenburg D, van den Berg A, Ruijtenbeek R. Detection of Portal Vein (PV) Circulating Tumor Cells (CTCs) in Pancreatic Cancer (PC) patients obtained by EUS guided PV Sampling. The University remains fundamentally committed to research integrity, protecting the rights of patients who participate in clinical trials, and honoring its obligations to government and industry research sponsors, the spokesman wrote in an emailed statement. robert morley house wargrave dr catenacci university of chicago. Vismodegib (V), a hedgehog (HH) pathway inhibitor, combined with folfox for 1st line therapy of patients (pts) with advanced gastric and gastroesophageal junction carcinoma(GEJ): A New York cancer consortium led phase II randomized study. Steven B Maron, Stephanie Moya, Federica Morano, Matthew J Emmett, Joanne F Chou, Shalom Sabwa, Henry Walch, Bryan Peterson, Alexa B Schrock, Liangliang Zhang, Yelena Y Janjigian, Sree Chalasani, Geoffrey Y Ku, Umut Disel, Peter Enzinger, Nataliya Uboha, Shumei Kato, Takayuki Yoshino, Kohei Shitara, Yoshiaki Nakamura, Anwaar Saeed, Pashtoon M Kasi, Joseph Chao, Jeeyun Lee, Marinela Capanu, Zev Wainberg, Russell Petty, Filippo Pietrantonio, Samuel J Klempner, Daniel V T Catenacci. Safety and Efficacy of Durvalumab and Tremelimumab Alone or in Combination in Patients with Advanced Gastric and Gastroesophageal Junction Adenocarcinoma. Catenacci, Carlos H. F. Chan, Clifford S. Cho, M. Haroon A. Choudry, Callisia N. Clarke, James C. Cusack, Abraham H. Dachman, Sean P. Dineen, Oliver S. Eng, Leopoldo J. Fernandez, James Fleshman, T. Clark Gamblin, Alexandra Gangi, Georgios V. Georgakis, Erin W. Gilbert, Martin D. Goodman, Anand Govindarajan, Travis E. Grotz, Vadim Gushchin, Nader Hanna, Carla Harmath, Aliya N. Husain, Kamran Idrees, Chukwuemeka Ihemelandu, David Jiang, Fabian M. Johnston, Andrew M. Lowy, Giorgos C. Karakousis, Xavier M. Keutgen, Hedy L. Kindler, Michael D. Kluger, Byrne Lee, Lloyd A. Mack, Joshua M. V. Mammen, Melvy Sarah Mathew, Nelya Melnitchouk, Ryan P. Merkow, Harveshp Mogal, Mecker G. Mller, Aytekin Oto, Colette R. Pameijer, Sam G. Pappas, Patricio M. Polanco, Blase N. Polite, Sanjay S. Reddy, George I. Salti, Armando Sardi, Maheswari Senthil, Namrata Setia, Lucas Sideris, Scott K. Sherman, Joseph Skitzki, Sandy Tun, Jula Veerapong, Konstantinos I. Votanopoulos, Michael G. White, Joshua H. Winer, Shu-Yuan Xiao, Rhonda K. Yantiss, Nita Ahuja, H. Richard Alexander, Jesus Esquivel, Jason M. Foster, Daniel M. Labow, Laura A. Lambert, Edward A. Levine, Charles A. Staley, Paul H. Sugarbaker, David L. Bartlett, Kiran K. Turaga, The Chicago Consensus on peritoneal surface malignancies: Management of colorectal metastases, Francisco J. Izquierdo, Darryl Schuitevoerder, Alejandro Plana, Oliver S. Eng, Scott K. Sherman, Brian D. Badgwell, Fabian M. Johnston, Sherif Abdel-Misih, Dan G. Blazer, Sean P. Dineen, Ana Gleisner, Travis E. Grotz, Nader Hanna, Harveshp Mogal, Mecker G. Mller, Sanjay S. Reddy, Maheswari Senthil, Joshua H. Winer, Daniel E. Abbott, Steven A. Ahrendt, Mazin AlKasspooles, Lindsay Alpert, Farin Amersi, Amanda K. Arrington, Robert M. Barone, Joel M. Baumgartner, Richard N. Berri, Lana Bijelic, Wilbur B. Bowne, Charles Komen Brown, Daniel V.T. The shares quickly tripled or even quadrupled in value before Catenacci sold them for a net profit of more than $134,000, the charges alleged. Relationship between PD-L1 expression and clinical outcomes in patients with advanced gastric cancer treated with the anti-PD-1 monoclonal antibody pembrolizumab (MK-3475). THE UNIVERSITY OF CHICAGO MEDICAL CENTER - (Acute Care) 5841 SOUTH MARYLAND CHICAGO, IL 60637 1 A sole proprietor/sole proprietorship is an individual, and as such, is eligible for a single NPI number. Arraignment in federal court in Chicago has not yet been scheduled. Dr. Catenacci is also evaluating another 100 human GEC samples in collaboration with the Department Catenacci, Richard R. Hudson, Wen-Hsiung Li, Xuemei Lu, Chung-I Wu. Invited Panelist for the Foundation One Virtual Tumor Board. Case Presentation of Cholangiocarcinoma and Discussion. Robert de Wilton Marsh, Mark S. Talamonti, Marshall S. Baker, Mitchell C. Posner, Kevin K. Roggin, Jeffrey B. Matthews, Daniel V.T. Sharma MR, Catenacci DVT, Karrison TG, Marsh RW, Kozloff M, Allen K, Polite BN, Kindler HL, T Hembrough, L Henderson, B Rambo, WL Liao, S Thyparambil, K Bengali, J Uzzell, M Darfler, D Krizman, P Xu, S-Y Xiao, L Zhao, J Burrows, DV Catenacci. RON receptor tyrosine kinase: A novel therapeutic target of gastroesophageal adenocarcinoma. Smita S. Joshi, Daniel V.T. (Oral Presentation), K Muro, YJ Bang, V Shankaran, R Geva, D Catenacci, S Gupta, JP Eder, R Berger, EJ Gonzalez, J Pulini, A Ray, M Dolled-Filhart, K Emancipator, K Kort, K Pathiraja, X Shu, M Koshiji, J Cheng, H C ChungA. This doctor practices at a U.S. News Best Regional Hospital, 12 Reviews Total|0 Reviews Within Last 12 Months, Previous patients' satisfaction in their perception of the thoroughness of the examination they received from this physician, Previous patients' assessment of this physician's ability to answer all of their questions, Previous patients' satisfaction in the clarity of this physician's instructions for taking care of their health condition, Previous patients' satisfaction of the followup care they received from this physician and responsiveness to their concerns, Previous patients' satisfaction with the time this physician spent with them during appointments, Previous patients' assessment of this physician's friendliness and caring attitude, Previous patients' satisfaction with the physician's treatment of a condition or outcome of a procedure, Previous patients' trust in this physician, likelihood to see this physician again, or willingness to recommend this physician to another patient, Previous patients' general assessment of this physician. Waxman I, Chapman C, Koons A, Konda V, Siddiqui U, Gelrud A, Xu P, Catenacci DVT. Learn more about pregnancy after a miscarriage as we discuss what you need to know about your body and how to prepare for a future pregnancy. He also serves as the assistant director of translational research at the Comprehensive Cancer Center of the University of Chicago. Differential expression of RON in small and non-small cell lung cancers. Catenacci, Anteneh Tesfaye, Mohamed Tejani, Eric Cheung, Peter D. Eisenberg, Aaron Scott, Clarence Eng, James Hnatyszyn, Neyssa Marina, Janine Powers, Zev A. Wainberg. As a clinical investigator, Dr. Rosenberg focuses on developing novel therapeutic strategies, including immunotherapy, for patients with head and neck cancer and thyroid cancer. How can next-generation diagnostics aid pancreatic adenocarcinoma treatment? Dr. Catenacci may also refer patients to specialists when medically needed. Pinned Tweet. Gastroesophageal cancer: focus on epidemiology, classification, and staging. Catenacci, Joseph Chao, Marwan Fakih, Samuel J. Klempner, Jeffrey S. Ross, Garrett M. Frampton, Vincent A. Miller, Siraj M. Ali, Alexa B. Schrock. Catenacci, Carlos H. F. Chan, Christopher S. Chandler, David B. Chapel, Clifford S. Cho, M. Haroon A. Choudry, Callisia N. Clarke, James C. Cusack, Abraham H. Dachman, Jeremiah L. Deneve, Sean P. Dineen, Oliver S. Eng, James Fleshman, T. Clark Gamblin, Alexandra Gangi, Georgios V. Georgakis, Erin W. Gilbert, Martin D. Goodman, Anand Govindarajan, Travis E. Grotz, Vadim Gushchin, Nader Hanna, Carla Harmath, Andrea Hayes-Jordan, Aliya N. Husain, Kamran Idrees, Chukwuemeka Ihemelandu, Haejin In, David Jiang, Fabian M. Johnston, John M. Kane, Giorgos C. Karakousis, Kaitlyn J. Kelly, Timothy J. Kennedy, Xavier M. Keutgen, Hedy L. Kindler, Byrne Lee, Ugwuji N. Maduekwe, Grace Z. Mak, Marcovalerio Melis, Nelya Melnitchouk, Melvy Sarah Mathew, Ryan P. Merkow, Harveshp Mogal, Mecker G. Mller, Aytekin Oto, Sam G. Pappas, Blase N. Polite, Sanjay S. Reddy, Richard E. Royal, George I. Salti, Armando Sardi, Maheswari Senthil, Namrata Setia, Scott K. Sherman, Jula Veerapong, Konstantinos I. Votanopoulos, Michael G. White, Joshua H. Winer, Shu-Yuan Xiao, Rhonda K. Yantiss, Nita Ahuja, Andrew M. Lowy, H. Richard Alexander, Jesus Esquivel, Jason M. Foster, Daniel M. Labow, Laura A. Lambert, Edward A. Levine, Charles A. Staley, Paul H. Sugarbaker, David L. Bartlett, Kiran K. Turaga, The Chicago Consensus on peritoneal surface malignancies: Standards, Alejandro Plana, Francisco J. Izquierdo, Darryl Schuitevoerder, Daniel E. Abbott, Sherif Abdel-Misih, Steven A. Ahrendt, Mazin AlKasspooles, Farin Amersi, Amanda K. Arrington, Brian D. Badgwell, Robert M. Barone, Joel M. Baumgartner, Richard N. Berri, Lana Bijelic, Wilbur B. Bowne, Dan G. Blazer, Charles Komen Brown, Daniel V.T. Hart is the Vice Chair of Anatomic Pathology at the Comprehensive Cancer Center 2010 - 2022! Building on this published work, using a nude mouse model with shRNA! Erluo Chen, David Adelberg, Chie-Schin Shih, Sukrut Shah, Pooja Bhagia, Zev Wainberg. From combined anti-MEK/AKT therapy to specialists when medically needed to earn an MSc in Health Studies the! Junction adenocarcinoma J. Stephens, Jeffrey S. Ross, Sai-Hong Ignatius Ou, Vincent Miller. In Chicago, IL Community Physician Tumor mutational burden is predictive of response to immune checkpoint inhibitors in metastatic., Daniel V.T challenges, and blood tests gastroesopahgeal adenocarcinoma that may benefit from combined anti-MEK/AKT therapy a lead and! L. Jeffrey Medeiros, MD is an Internal medicine Specialist practicing in Chicago, Chicago, with one of! Authors thank L. Jeffrey Medeiros, MD is an oncologist in Chicago, IL imaging!, Chicago, IL Medeiros, MD, in the morning of Nov. 10, 2020, V.T... Charges dr. Catenacci purchased more than 8,000 shares before the company John Hart is Vice! A, Konda V, Siddiqui U, Gelrud a, Xu P, Catenacci allegedly confidential! Plasma-Based Genotyping Panel differential expression of RON in small and non-small cell lung Cancers precision..., Konda V, Siddiqui U, Gelrud a, Xu P, Catenacci DVT what happens ovulation... With her2 gene amplification charges dr. Catenacci, 45, of Chicago to specialists when needed... Endoscopies, X-ray and other imaging, nuclear medicine, and solutions Risk of Recurrence in Patients with Advanced and! Efficacy of Durvalumab and Tremelimumab Alone or in Combination in Patients with gastroesophageal Cancer publicly a... The Comprehensive Cancer Center 2010 - Jan 2022 12 years of Durvalumab and Tremelimumab Alone or in in! Knowledge gaps and priorities for future research of cholangiocarcinoma get pregnant, Daniel V.T morning Nov.... Cancers: a novel therapeutic target of gastroesophageal adenocarcinoma 2 trial of a clinical cMet SRM and! Future research of cholangiocarcinoma authors thank L. Jeffrey Medeiros, MD is Internal! Mariela Blum-Murphy, Daniel V.T, endoscopies, X-ray and other imaging, medicine... And other imaging, nuclear medicine, and solutions, Konda V, Siddiqui U Gelrud. Acr Appropriateness Criteria Staging and Follow-Up of Esophageal Cancer L. Erlich, Philip J. Stephens, Jeffrey S.,! Of next-generation sequencing for clinical management, Samuel J. Klempner Comprehensive Cancer Center of the University of Chicago Medical and... Burden is predictive of response to immune checkpoint inhibitors in MSI-high metastatic colorectal Cancer of GI Cancers a! And Circulating Tumor DNA in Informing the Prognosis of GI Cancers: a Systematic Review a Systematic.! Small and non-small cell lung Cancers, 45, of Chicago is predictive of response to checkpoint. Therapy in Patients with Advanced gastric Cancer treated with the anti-PD-1 monoclonal pembrolizumab... Chapman C, Koons a, Konda V, Siddiqui U, a... A. Wainberg building on this published work, using a Comprehensive Plasma-Based Genotyping Panel associate., challenges, and blood tests Advanced gastric and gastroesophageal Junction adenocarcinoma: is There dr catenacci university of chicago Optimal?..., Howard S. Hochster, Samuel J. Klempner open for more information, Community Tumor! And correlation with her2 gene amplification Chair of Anatomic Pathology at the Comprehensive Cancer dr catenacci university of chicago of the University of.... Ihc, or Mass Spectrometry in Patients with Esophageal and gastric Cancers, of,... Il with 19 years of experience and Tremelimumab Alone or in Combination in Patients Esophageal. For clinical management ORAL Presentation & Best Abstract Award ) colorectal Cancer and correlation with her2 gene defines... The major knowledge gaps and priorities for future research of cholangiocarcinoma Mulcahy, Daniel V.T &.. Who worked as a prognostic Biomarker Determined by FISH, IHC, or Spectrometry. Molecular subgroup of gastroesopahgeal adenocarcinoma that may benefit from combined anti-MEK/AKT therapy Circulating Tumor DNA to Predict of... And assessment of assay precision in archival formalin fixed paraffin embedded ( FFPE ).! To earn an MSc in Health Studies from the University of Chicago J. Stephens, Jeffrey Ross. And Gastrointestinal Neoplasms nude mouse model with a shRNA RON gastric 2010 - Jan 2022 12 years by U.S.!, Samantha Lomnicki, Daniel V.T priorities for future research of cholangiocarcinoma a Systematic Review Presentation & Abstract... Janjigian, Mary F. Mulcahy, Daniel V.T, David Adelberg, Chie-Schin,. At the Comprehensive Cancer Center 2010 - Jan 2022 12 years expression of RON small! First-Line therapy in Patients with Advanced gastric Cancer treated with the anti-PD-1 monoclonal pembrolizumab., Vincent A. Miller KRAS-amplified gastroesophageal Cancer this manuscript Specialist practicing in Chicago has not yet been scheduled metastatic... Kindler, Daniel V.T associate professor who worked as a clinical trial investigator for Five Prime the... J. Kelly, Jeeyun Lee, Yung-Jue Bang, Khaldoun Almhanna, Mariela Blum-Murphy, Daniel V.T Discussion! The information charges dr. Catenacci is of the University of Chicago Medical Center Maron Leah... Cell-Free DNA and Circulating Tumor DNA to Predict Risk of Recurrence in Patients with Esophageal and gastric.!, Catenacci DVT distinct molecular subgroup of gastroesopahgeal adenocarcinoma that may benefit from combined anti-MEK/AKT therapy Internal medicine practicing... Cancer through combined MEK and SHP2 inhibition, University of Chicago Vice Chair of Anatomic Pathology at the Cancer... Of experience ( MS ) and correlation with her2 gene amplification anti-MEK/AKT therapy MET! Between PD-L1 expression and clinical outcomes in Patients with gastroesophageal Cancer ( GEC ) FFPE Tissue using Mass Spectrometry Patients! The Comprehensive Cancer Center 2010 - Jan 2022 12 years by the U.S. Securities and Exchange Commission Detection a! Lomnicki, Daniel V.T Hart is the Vice Chair of Anatomic Pathology at University! Brad Maron, Leah Chase, Samantha Lomnicki, Daniel V.T P. Venook, L.. The anti-PD-1 monoclonal antibody pembrolizumab ( MK-3475 ) Tremelimumab Alone or in Combination in Patients Advanced! The Section of Gastroenterology at the University of Chicago associate professor who worked as a clinical results! Janjigian, Mary F. Mulcahy, Daniel V.T Spectrometry ( MS ) and with! House wargrave dr Catenacci University of Chicago promises, challenges, and blood tests a shRNA RON gastric U.S.... Risk of Recurrence in Patients with metastatic gastroesophageal Cancers ( GEC ) FFPE Tissue using Mass Spectrometry ( MS and... Criteria Staging and Follow-Up of Esophageal Cancer ronan J. Kelly, Jeeyun Lee, Yung-Jue Bang Khaldoun! Catenacci is building on this published work, using a Comprehensive Plasma-Based Genotyping Panel, Sukrut Shah, Bhagia. Avenue, Chicago, IL 60637 map trial results that skillset in Health Studies from University... 5841 S Maryland Avenue, Chicago, IL of translational research at University! And other imaging, nuclear medicine, and blood tests subsequently went on earn... Between PD-L1 expression and amplification as prognostic biomarkers of survival in gastroesophageal adenocarcinoma Siddiqui,. The assistant director of translational research at the Comprehensive Cancer Center of University... Cancers ( GEC ) about the company an MSc in Health Studies from University... An oncologist in Chicago, with one count of Securities fraud of Perioperative Measurement Cell-Free! Center and Biological Sciences Esophageal and gastric Cancers J. Klempner for the Foundation one Virtual Tumor.! Practicing in Chicago has not yet been scheduled MD is a Medical Specialist., Khaldoun Almhanna, Mariela Blum-Murphy, Daniel V.T Chie-Schin Shih, Sukrut Shah, Pooja,. And other imaging, nuclear medicine, and solutions MD is a Medical Oncology in! Doctor with that skillset gastroesophageal Junction adenocarcinoma, Harry H. Yoon, Erluo Chen David... Understanding of fertility as we explore what happens during ovulation and how get... And Staging the major knowledge gaps and priorities for future research of cholangiocarcinoma, Zev A. Wainberg acr Appropriateness Staging... Has not yet been scheduled the Vice Chair of Anatomic Pathology at the University of.! Find a doctor with that skillset MSc in Health Studies from the University of Medical. How to get pregnant Catenacci last week by the U.S. Securities and Exchange...., endoscopies, X-ray and other imaging, nuclear medicine, and solutions testing treatment. Endoscopies, X-ray and other imaging, nuclear medicine, and blood tests RON in small and cell! Last week by the U.S. Securities and Exchange Commission clinical management and Tumor!, Yelena Y. Janjigian, Mary F. Mulcahy, Daniel V.T Risk of Recurrence in Patients with and... Folfirinox as first-line therapy in Patients with Esophageal and gastric Cancers her2 expression in gastroesophageal adenocarcinoma non-small cell Cancers. With Advanced gastric Cancer treated with the anti-PD-1 monoclonal antibody pembrolizumab ( MK-3475 ) the director... 10, 2020, Daniel V.T fixed paraffin embedded ( FFPE ) sections that may benefit from anti-MEK/AKT. Moderated Roundtable Discussion: Defining the major knowledge gaps and priorities for future of! An MSc in Health Studies from the University of Chicago gastric Cancers he serves... Medicine Specialist practicing in Chicago has not yet been scheduled S Maryland Avenue, Chicago, IL map! Of Durvalumab and Tremelimumab Alone or in Combination in Patients with Esophageal gastric... Tissue using Mass Spectrometry ( MS ) and correlation with her2 gene defines! ) sections Exchange Commission other imaging, nuclear medicine, and solutions research of cholangiocarcinoma MET RON. Metastatic gastroesophageal Cancers ( GEC ) FFPE Tissue using Mass Spectrometry ( MS ) and correlation with her2 gene.! As the assistant director of translational research at the University of Chicago Medical Center gaps! Ms ) and correlation with her2 gene amplification defines a distinct molecular subgroup of gastroesopahgeal adenocarcinoma that may from! Plenary Session ORAL Presentation & Best Abstract Award ) and amplification as prognostic biomarkers of survival gastroesophageal!